

Systematic Review Efficacy of Deep Brain Stimulation for Camptocormia in Parkinson's Disease: A Systematic Review and Meta-Analysis

Fuli Wang¹, Lili He¹, Hecong Zhao¹, Xiaoyan Guo^{1,*}

¹Department of Neurology, The Affiliated Hospital of Southwest Medical University, 646000 Luzhou, Sichuan, China

*Correspondence: gxy19800312@163.com (Xiaoyan Guo)

Academic Editor: Gernot Riedel

Submitted: 14 August 2022 Revised: 25 September 2022 Accepted: 17 October 2022 Published: 5 January 2023

Abstract

Background: Camptocormia is one of the most common postural disorders of Parkinson's disease (PD) which has limited treatment options. In this review, we summarize the efficacy of deep brain stimulation (DBS) for camptocormia in PD. Methods: The PubMed (ht tps://pubmed.ncbi.nlm.nih.gov/) and EMBASE databases (https://www.embase.com/) were searched for the terms "Parkinson Disease" and "camptocormia" in combination with "deep brain stimulation". We then explored the efficacy of DBS for camptocormia by statistical analysis of the bending angle, the Unified Parkinson's Disease Rating Scale III (UPDRS-III) and L-dopa equivalent daily dose (LEDD), and by evaluating the prognosis after DBS. Results: Twenty articles that reported results for 152 patients were included in this review. These comprised 136 patients from 16 studies who underwent subthalamic nucleus deep brain stimulation (STN-DBS), and 13 patients from 3 studies who underwent globus pallidus internus deep brain stimulation (GPi-DBS). One study used both STN-DBS (2 patients) and GPi-DBS (one patient). After 3-21 months of follow-up, the mean bending angle during the Off-period was significantly reduced compared to pre-DBS (31.5 \pm 21.4 vs. 53.6 \pm 22.7, respectively; p < 0.0001). For the STN-DBS trials, the mean post-operative bending angles during both Off- and On-periods were significantly reduced compared to pre-operative (32.1 ± 22.7 vs. 55.4 ± 24.1 , p = 0.0003; and 33.1 ± 21.5 vs. 43.7 ± 20.6 , p = 0.0003, respectively). For GPi-DBS, the mean bending angle post-DBS during the Off-period was considerably lower than pre-DBS (28.5 ± 10.7 vs. 42.9 ± 9.9 , p < 0.001). The decrease in bending angle after DBS was negatively correlated with the duration of camptocormia (R = -0.433, p = 0.013), whereas positively associated with the pre-bending angle (R = -0.433, p = 0.013), whereas positively associated with the pre-bending angle (R = -0.433, p = 0.013), whereas positively associated with the pre-bending angle (R = -0.433, p = 0.013), whereas positively associated with the pre-bending angle (R = -0.433, p = 0.013), whereas positively associated with the pre-bending angle (R = -0.433, p = 0.013). 0.352, p = 0.03). Conclusions: DBS is an effective treatment for camptocormia in PD. Patients in the early stage of camptocormia with more significant bending angle may benefit more from DBS.

Keywords: camptocormia; Parkinson's disease; deep brain stimulation

1. Introduction

Camptocormia is a common postural deformity in Parkinson's disease (PD), with a prevalence estimated to range from 3% to 18% [1]. It is described as forward flexion of the thoracolumbar spine, which aggravates in the standing position and disappears in the supine position. In addition to PD, other potential etiologies for camptocormia include axial myopathy, joint degenerative diseases, and atypical PD such as multiple system atrophy and progressive supranuclear palsy. However, the prevalence of camptocormia in PD (22.5%) is much higher than in other diseases [2]. Camptocormia may aggravate rapidly with the progression of PD and will be accompanied by dyskinesias, falls, severe back pain, difficulty in eating, and even respiratory failure, all of which significantly impact the quality of life and increase motor disability and care burden.

Camptocormia can be classified into lower camptocormia (total camptocormia angle $\geq 30^{\circ}$) and upper camptocormia (upper camptocormia angle $\geq 45^{\circ}$). The total camptocormia (TCC) angle is defined as the angle between the line from the lateral malleolus to the L5 spinous process, and the line between the C7 spinous process and the L5 spinous process. The upper camptocormia (UCC) angle is defined as the angle between the line from the vertebral fulcrum to the C7 spinous process and the L5 spinous process [3,4].





Fig. 1. Flowchart of study selection.



Publisher's Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Fig. 2. Comparison bending angle between pre- and post-DBS (Off-period). DBS, deep brain stimulation.

The pathogenesis of camptocormia is unclear, with several potential contributing factors including dystonia, myopathy, proprioceptive disintegration, medication effects and soft tissue changes. Paraspinal dystonia is often observed in the early stage of camptocormia, followed gradually combined with focal myopathy and soft tissue changes [5].

Camptocormia usually appears in the advanced stage of PD, and has generally proved refractory to pharmacological treatment. Some studies have reported that dopaminergic drugs may even induce or aggravate camptocormia, especially high-dose and long-term use of levodopa and dopamine receptor agonists [6,7]. The effectiveness of other therapeutic options such as lidocaine injection, botulinum toxin injection and rehabilitation training remains controversial. Complications from spinal surgery are common [5]. In recent years, deep brain stimulation (DBS) has been used to treat camptocormia in PD. Given the inconsistent results reported so far, we conducted this meta-analysis to assess the efficacy of DBS for camptocormia in PD patients.

2. Materials and Methods

Selection of Studies for Analysis

We examined 46 articles from PubMed and 104 articles from EMBASE. The inclusion criteria were: (1) definitive diagnosis of PD and camptocormia, with the camptocormia related to PD; (2) Intervention with DBS; (3) English language study. The exclusion criteria were: (1) Review article; (2) Articles with missing or non-extractable data; (3) Duplicate articles or those with repeat clinical data. Twenty studies containing a total of 152 patients [3,8–26] met all of the criteria and were included in the analysis. Three studies used globus pallidus internus deep brain stimulation (GPi-DBS), 16 used subthalamic nucleus deep brain stimulation (STN-DBS), and one study used both (Fig. 1). And the CRD number of the systematic review on the PROSPERO is 353766.

3. Data Extraction

Information extracted from the selected papers included authors, year of publication, type of research, number of participants, age, gender, PD duration, camptocormia duration, bending angles (in both On and Off periods), the

tics (version 17.0, IBM SPSS Inc, Chicago, IL, USA) were used for statistical analysis. Mean differences and 95% confidence intervals for the variables are presented as for-

tients) [27].

3.2 Statistical Analysis

3.1 Risk of Bias

confidence intervals for the variables are presented as forest plots, with the Chi-squared and I² tests used to quantitatively evaluate the heterogeneity between studies. The fixed-effects model was adopted when I² \leq 50%, while the random-effects model was used when I² >50%. For a more appropriate statistical analysis, all STN-DBS and GPi-DBS studies containing less than 5 patients were incorporated into new groups named case reports. The difference in bending angle change between STN-DBS and GPi-DBS was studied by using the *t*-test. Pearson correlation analysis was employed to evaluate associations between the reduced bending angle of camptocormia after surgery and various clinical features including age, duration of PD and camptocormia, LEDD, pre-bending angle and UPDRS-III. A *p* value of <0.05 was considered statistically significant.

Unified Parkinson's Disease Rating Scale III (UPDRS-III)

score (in both On and Off periods), mean follow-up time,

and the L-dopa equivalent daily dose (LEDD) assessed both

Prospective observational or case-controlled study; (III)

Retrospective study; (IV) Case report or series (<10 pa-

Cochrane Centre, Copenhagen, Denmark) and SPSS Statis-

The quality of articles was evaluated according to the following criteria: (I) Randomized controlled trial; (II)

Review Manager software (version 5.3, The Nordic

pre- and post-DBS (Tables 1,2, Ref. [3,8-26]).

4. Results

Details of the 20 studies and 152 participants included in this meta-analysis are listed in Tables 1,2. The patients were comprised of 55 males, 45 females and 52 with unknown gender. STN-DBS was employed as the intervention in 16 studies (136 patients) and GPi-DBS (13 patients) in three studies. One study used both STN-DBS (2 patients) and GPi-DBS (one patient). Comparisons of the clinical data between pre- and post-DBS periods are shown in Figs. 2,3. After an average of 3–21 months follow-up post DBS, the mean bending angle assessed during the Offperiod was markedly lower than during the pre-operative



	ative bendi	ng angle	posto	perative	bendin	g angle		Mean Differen	e	Mea	an Difference	
Mean	SD	Toi			SD		al Weigh				andom, 95% (CI
42.4	7.5			5.5	12	2					-	
84	29.5				28.3							
73	18.6		6	17	10.3		6 17.99				-	-
			15	8.5							• •	
51.4	10.9				10.3						-	
01.1	10.0		10 2	0.1	10.0		0 21.17	20.00 [10.11, 0				
			75			7	5 100.0%	28.68 [13.17.4 4	.201		•	
Chi2 - 50 I	51 df - 4 (5			/				20.00 [.0.11, 1				
		< 0.0000	51), 1 - 55	'0							0 50	100
·	,									nonerrec	ctive enective	1
preor	norativo a	nale				le durin				Mean [lifference	
						Waiak						
										IV, Kano	10m, 95% CI	
											•	
35.2	2 12.5	27	32.9	14	27	20.89	% 2	.30 [-4.78, 9.38]		-	- 	
59.6	3 25.5	17	51.9	28.9	17	7.49	% 7.70	[-10.62, 26.02]			<u> </u>	
53.2	2 10	25	34.3	15	25	20.89	% 18.9	0 [11.83, 25.97]				
												_
55.5	0 10.5	14	30.7	21.1	14	10.8	/0 10.	ou [2.77, 30.83]			1	
		105			10F	100.00	× 104	SO [A OA 16 AA]			•	
0.0612	10 10 -16		00). 12 - 0	20/	105	100.0	/0 10.0	JJ [4.34, 10.44]			↓ • •	
		э (Р = 0	.02); I ² = 6	2%					-50	-25	0 25	5 50
.64 (P = 0	0.0003)								00			, 00
										nonencouve	o cheotive	
				B1: UP	DRS-III	during	Off-perio	d				
			postop									
Mean	SD	Total	Mean	S	D T					IV, Rar	<u>ndom, 95% C</u>	:
46.2	19.6	11	23.8	13	.9	11 '	14.4%	22.40 [8.20, 36.6	0]			
42.4	10.7	17	18.8	8	.8	17 2	23.7%	23.60 [17.01, 30.1	91			
48.3	16.6	6	15	1	0	6						_
55.1	17.4	15		12	2							
00.1			2110	12								
E0 C	47.0			10				1 11 70 91 00 00				-
50.6	17.2	8	20.4	10	••		14.7%	30.20 [16.27, 44.1	3]			-
50.6 45.5	17.2 21.3	8 13	20.4 41.5		.4 1	-		30.20 [16.27, 44.1 4.00 [-9.03, 17.0	3]		+	-
		13			••	13	14.7% 3 15.7%	4.00 [-9.03, 17.0	3] 3]		+	-
45.5	21.3	13 70	41.5	1	••	13	14.7% 3 15.7%		3] 3]		•	-
45.5 Chi ² = 12	21.3 2.79, df = 5	13 70	41.5	1	••	13	14.7% 3 15.7%	4.00 [-9.03, 17.0	3] 3]		•	- - 50 100
45.5	21.3 2.79, df = 5	13 70	41.5	1	••	13	14.7% 3 15.7%	4.00 [-9.03, 17.0	3] 3] 8]		0 ve effective	- 50 100
45.5 Chi ² = 12	21.3 2.79, df = 5	13 70	41.5	6	1	13 70 1	14.7% 3 15.7%	4.00 [-9.03, 17.0 23.92 [16.27, 31.54	3] 3] 8]		•	- 50 100
45.5 Chi ² = 12 13 (P < 0.1	21.3 2.79, df = 5	13 70 (P = 0.0	41.5 3); I ² = 619	6	DRS-III	13 70 10	14.7% : 15.7% 00.0% 2 On-period	4.00 [-9.03, 17.0 23.92 [16.27, 31.54	3] 3] 8]	noneffecti	•	-
45.5 Chi ² = 12 13 (P < 0.1	21.3 2.79, df = 5 00001)	13 70 (P = 0.0	41.5 3); I ² = 619	1 6 B2: UP erative I	DRS-III	13 70 10	14.7% : 15.7% 00.0% 2 On-period	4.00 [-9.03, 17.0 2 3.92 [16.27, 31.5 4 d	3] 3] 6] -100	noneffecti Mean	ve effective	
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u>	21.3 2.79, df = 5 00001) rative UPD SD	13 70 (P = 0.0 RS-III Total	41.5 3); I ² = 61% postop	6 B2: UP erative I	DRS-III UPDRS- 50	13 70 10 during 0 -III Total V	14.7% : 15.7% 00.0% 2 On-period	4.00 [-9.03, 17.0 23.92 [16.27, 31.54 d Mean Difference IV. Random, 95%	3] 3] 6] -100	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u> 33.5	21.3 2.79, df = 5 00001) rative UPD <u>SD</u> 12.8	13 70 (P = 0.0 RS-III <u>Total</u> 11	41.5 3); I ² = 61% postop <u>Mean</u> 17.9	B2: UP erative I 5 6	DRS-III UPDRS- <u>5D</u>	13 - 70 10 during (-III <u>Total V</u> 11	14.7% 3 15.7% 00.0% 2 Dn-period <u>Veight</u> 16.4%	4.00 [-9.03, 17.0 23.92 [16.27, 31.54 d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0	3] 3] -100 <u>CI</u> 6]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 [3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5	21.3 2.79, df = 5 00001) rative UPD <u>SD</u> 12.8 10.8	13 70 (P = 0.0 RS-III <u>Total</u> 11 17	41.5 3); I ² = 61% postop <u>Mean</u> 17.9 16.5	B2: UP B2: UP Brative I S 6	DRS-III UPDRS- 5D .4 8	13	14.7% 3 15.7% 00.0% 2 Dn-period Veight 16.4% 21.3%	4.00 [-9.03, 17.0 3.92 [16.27, 31.54 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3	s] 3] -100 CI 6] 9]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41	21.3 2.79, df = 5 00001) ative UPD <u>SD</u> 12.8 10.8 14.7	13 70 (P = 0.0 RS-III <u>Total</u> 11 17 6	41.5 3); I ² = 619 postop <u>Mean</u> 17.9 16.5 15	B2: UP B2: UP Brative I S 6	DRS-III UPDRS- 50 1 .4 8 10	13	14.7% 3 15.7% 00.0% 2 Dn-period Veight 1 16.4% 21.3% 8.2%	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2	3] 3] -100 <u>CI</u> 6] 9] 3]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 3 (P < 0. preoper <u>Mean</u> 33.5 23.5 41 22.5	21.3 2.79, df = 5 00001) ative UPD SD 12.8 10.8 14.7 4.3	13 70 (P = 0.0 RS-III Total 11 17 6 25	41.5 3); I ² = 619 postop <u>Mean</u> 17.9 16.5 15.2	6 B2: UP erative I S 6	DRS-III UPDRS- 5D 7 .4 8 10 .9	13	14.7% 3 15.7% 00.0% 2 Dn-period 16.4% 21.3% 8.2% 3 33.4%	4.00 [-9.03, 17.0 3.92 [16.27, 31.50 d Mean Difference <u>IV. Random. 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 6.60 [11.77, 40.2 7.30 [5.27, 9.3	3] 3] -100 CI 6] 9] 3] 3]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41	21.3 2.79, df = 5 00001) ative UPD <u>SD</u> 12.8 10.8 14.7	13 70 (P = 0.0 RS-III <u>Total</u> 11 17 6	41.5 3); I ² = 619 postop <u>Mean</u> 17.9 16.5 15	6 B2: UP erative I S 6	DRS-III UPDRS- 50 1 .4 8 10	13	14.7% 3 15.7% 00.0% 2 Dn-period Veight 1 16.4% 21.3% 8.2%	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2	3] 3] -100 CI 6] 9] 3] 3]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 3 (P < 0. preoper <u>Mean</u> 33.5 23.5 41 22.5	21.3 2.79, df = 5 00001) ative UPD SD 12.8 10.8 14.7 4.3	13 70 (P = 0.0 RS-III 11 17 6 25 13	41.5 3); I ² = 619 postop <u>Mean</u> 17.9 16.5 15.2	6 B2: UP erative I S 6	DRS-III UPDRS- 5D 7 .4 8 10 .9	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 2 00.0% 2 Dn-period Veight 16.4% 21.3% 33.4% 20.7%	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5	3] 3] -100 €] 6] 9] 3] 3] 4]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8	21.3 2.79, df = 5 00001) ative UPD SD 12.8 10.8 14.7 4.3 7.8	13 70 (P = 0.0 RS-III 11 17 6 25 13 72	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5	B2: UP Brative I S 6 1 2 9	DRS-III UPDRS- 5D 7 .4 8 10 .9	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 00.0% 2 Dn-period 16.4% 21.3% 8.2% 3 33.4%	4.00 [-9.03, 17.0 3.92 [16.27, 31.50 d Mean Difference <u>IV. Random. 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 6.60 [11.77, 40.2 7.30 [5.27, 9.3	3] 3] -100 €] 6] 9] 3] 3] 4]	noneffecti Mean	ve effective Difference	
45.5 Chi ² = 12 [3 (P < 0.] preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10	21.3 2.79, df = 5 00001) 2.8 12.8 10.8 14.7 4.3 7.8 0.91, df = 4	13 70 (P = 0.0 RS-III 11 17 6 25 13 72	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5	B2: UP Brative I S 6 1 2 9	DRS-III UPDRS- 5D 7 .4 8 10 .9	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 2 00.0% 2 Dn-period Veight 16.4% 21.3% 33.4% 20.7%	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5	3] 3] -100 €] 6] 9] 3] 3] 4]	Mear IV, Rau	ve effective	51
45.5 Chi ² = 12 I3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8	21.3 2.79, df = 5 00001) 2.8 12.8 10.8 14.7 4.3 7.8 0.91, df = 4	13 70 (P = 0.0 RS-III 11 17 6 25 13 72	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5	B2: UP Brative I S 6 1 2 9	DRS-III UPDRS- 5D 7 .4 8 10 .9	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 2 00.0% 2 Dn-period Veight 16.4% 21.3% 33.4% 20.7%	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5	3] 3] -100 €] 6] 9] 3] 3] 4]	Meam IV. Rau	ve effective Difference	
45.5 Chi ² = 12 [3 (P < 0.] preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10	21.3 2.79, df = 5 00001) 2.8 12.8 10.8 14.7 4.3 7.8 0.91, df = 4	13 70 (P = 0.0 RS-III 11 17 6 25 13 72	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5	B2: UP Brative I S 6 1 2 9	DRS-III UPDRS- 5D 7 .4 8 10 .9	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 2 00.0% 2 Dn-period Veight 16.4% 21.3% 33.4% 20.7%	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5	3] 3] -100 €] 6] 9] 3] 3] 4]	Meam IV. Rau	ve effective	51
45.5 Chi ² = 12 [3 (P < 0.] preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10	21.3 2.79, df = 5 00001) 2.8 12.8 10.8 14.7 4.3 7.8 0.91, df = 4	13 70 (P = 0.0 RS-III 11 17 6 25 13 72	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5	B2: UP Brative I S 6 1 2 9	DRS-III UPDRS- 3D .4 8 10 .9 .4	13 - 70 10 during 0 - -III - Total M 11 - 6 - 25 - 13 -	14.7% 3 15.7% 2 00.0% 2 Dn-period Veight 16.4% 21.3% 33.4% 20.7%	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5	3] 3] -100 €] 6] 9] 3] 3] 4]	Meam IV. Rau	ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10 01 (P < 0.1	21.3 2.79, df = 5 00001) ative UPD 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001)	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0	41.5 3); l ² = 619 <u>Mean</u> 17.9 16.5 15.2 19.5 3); l ² = 639	B2: UP erative I S 6 2 9	DRS-III UPDRS- 50 7 .4 8 10 .9 .4 .4 .4	13 70 10 during 0 -III Total 11 17 25 13 72	14.7% 3 15.7% 00.0% 2 Dn-period 16.4% 21.3% 8.2% 33.4% 20.7% 00.0%	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference IV. Random, 95% 15.80 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.5 9.52 [4.86, 14.1	3] 3] -100 €] 6] 9] 3] 3] 4]	IV. Rai	ve effective	51
45.5 Chi ² = 12 I3 (P < 0. preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10 D1 (P < 0.	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001)	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0	41.5 3); I ² = 61% Mean 17.9 16.5 155 15.2 19.5 3); I ² = 63%	B2: UP erative I 6 2 9 %	DRS-III UPDRS- 50 1 4 8 10 9 9 .4 C: 1 DD	13 - 70 10 during 0 -III Total W 11 17 6 25 13 72 13	14.7% : 15.7% 00.0% 2 0n-period Veight 16.4% 21.3% 33.4% 20.7% 00.0% Mear	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference IV. Random, 95% 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 h Difference	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 41 22.5 23.8 Chi ² = 10 01 (P < 0.1 preope <u>Mean</u>	21.3 2.79, df = 5 00001) ative UPD 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) ative LEI SD	13 70 (P = 0.0 RS-III 17 17 6 25 13 72 (P = 0.0 0D Total	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5 3); I ² = 63% <u>Mean</u>	6 B2: UP erative L S SD	1 DRS-III UPDRS. 50 	13 70 11 during (11 11 III 17 12 13 12 13 72 1 13 LEDD Weight 11	14.7% : 15.7% : 00.0% 2 Dn-period /eight 16.4% : 21.3% : 33.4% : 20.7% : 00.0% : Mear	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.34, 10.5 9.52 [4.86, 14.1 h Difference <u>V. Fixed, 95% CI</u>	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 Preoper Mean 33.5 23.5 23.5 23.8 Chi ² = 10 01 (P < 0.1 Preoper Mean 674.2	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) erative LEI <u>SD</u> 267.8	13 70 (P = 0.0 RS-III 111 17 6 25 13 72 (P = 0.0 DD Total 6	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 15.2 19.5 3); I ² = 639 postopera <u>Mean</u> 475.5 2	6 B2: UP erative I S 6 7 2 9 9 % *tive LE <u>SD</u> 44.1	DRS-III UPDRS- 50 1 4 8 10 9 9 4 4 8 10 9 9 4 4 0 0 0 0 7 0 0 7 0 1 6	13	14.7% : 15.7% : 00.0% 2 Dn-period : Veight : 16.4% : 21.3% : 8.2% : 33.4% : 20.7% : 00.0% : Mear : 198.70	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random. 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.7, 9.3 4.30 [-2.34, 10.5 9.52 [4.86, 14.1 h Difference <u>IV. Fixed. 95% CI</u> [-91.24, 488.64]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.) preoper <u>Mean</u> 33.5 23.5 411 22.5 23.8 Chi ² = 10 D1 (P < 0.) preope <u>Mean</u> 674.2	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0.91, df = 4 0001) 0.91, df = 4 0001)	13 70 (P = 0.0 RS-III 11 17 6 25 5 13 72 (P = 0.0 DD Total 6 17	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.2 19.5 3); I ² = 63% <u>Mean</u> 475.5 2 378.9 1	6 B2: UP S 6 6 7 2 9 9 % %	DRS-III UPDRS- 5 <u>D</u> .4 .4 .8 .0 .9 .4 .4 .0 .9 .4 .4 .0 .0 .4 .4 .7	13 70 11 during (11 11 11 17 : 6 125 : 72 1 72 1 25 : 72 1 : 5 : 72 1 : : 5,7% : 31.9% : : : : : :	14.7% : 15.7% : 200.0% 2 200.0% 2 200.0	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference [V. Random, 95% 15.60 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 Difference V. Fixed, 95% CI [-91.24, 488.64] [110.81, 356.79]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 Preoper <u>Mean</u> 33.5 23.5 23.8 Chi ² = 10 01 (P < 0.1 Preoper <u>Mean</u> 674.2 612.7 1,044	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0001 0001 0001 0001 0001 0001 00	13 70 (P = 0.0 (P = 0.0 Total 11 17 72 (P = 0.0 CD Total 6 17 25	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.5 19.5 3); I ² = 63% <u>Mean</u> 475.5 2 378.9 1 561 2	6 B2: UP S 6 6 7 2 9 8 % %	DRS-III UPDRS- 3D 1 .4 8 10 .9 .9 .4 4 C; 1 DD 1 0 1 7 6 6 17 25	13 70 11 during (11 III 11 17 16 25 13 72 1 LEDD Weightt 5.7% 31.9% 25.4% 25.4%	44.7% : 15.7% : 15.7% : 200.0% 2 200.0% 2 21.3% : 21.3% : 2	4.00 [-9.03, 17.0 3.92 [16.27, 31.50 3.92 [16.27, 31.50 4 Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 h Difference <u>IV. Fixed, 95% CI</u> [-91.24, 488.64] [10.81, 356.79] [345.15, 620.85]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	5 <u>1</u>
45.5 Chi ² = 12 3 (P < 0.) preoper <u>Mean</u> 33.5 23.5 411 22.5 23.8 Chi ² = 10 D1 (P < 0.) preope <u>Mean</u> 674.2	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0.91, df = 4 0001) 0.91, df = 4 0001)	13 70 (P = 0.0 RS-III 11 17 6 25 5 13 72 (P = 0.0 DD Total 6 17	41.5 3); I ² = 61% <u>Mean</u> 17.9 16.5 15.5 19.5 3); I ² = 63% <u>Mean</u> 475.5 2 378.9 1 561 2	6 B2: UP S 6 6 7 2 9 9 % %	DRS-III UPDRS- 5 <u>D</u> .4 .4 .8 .0 .9 .4 .4 .0 .9 .4 .4 .0 .0 .4 .4 .7	13 70 11 during (11 11 11 17 : 6 125 : 72 1 72 1 25 : 72 1 : 5 : 72 1 : : 5,7% : 31.9% : : : : : :	44.7% : 15.7% : 15.7% : 200.0% 2 200.0% 2 21.3% : 21.3% : 2	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference [V. Random, 95% 15.60 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 Difference V. Fixed, 95% CI [-91.24, 488.64] [110.81, 356.79]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 23.8 Chi ² = 10 01 (P < 0. preope Mean 674.2 612.7 1,044	21.3 2.79, df = 5 00001) 12.8 10.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) erative LEI 267.8 230.4 287.5 798.6	13 70 (P = 0.0 Total 11 17 6 25 13 72 (P = 0.0 DD Total 6 17 25 15	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 459	6 B2: UP S 6 7 2 9 % * * * * * * * * * * * * *	DRS-III UPDRS- 50 4.4 8 10 9.9 .4 C: 1 0 DD Total 1 6 17 25 5 15	13	14.7% : 15.7% 2 15.7% 2 200.0% 2 200.0% 2 200.7% 2 00.0% 2 198.70 233.80 00.0% 483.00 506.71	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random. 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.34, 10.5 9.52 [4.86, 14.1 10.16] 9.52 [4.86, 14.1 10.16]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.) preoper Mean 33.5 23.5 411 22.5 23.8 Chi ² = 10 11 (P < 0.) preoper Mean 674.2 612.7 1,044 965.7 616.5	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0.91, df = 4 0001) 0.91, df = 4 0001) 0.92, df = 2 202, 4 287, 5 798, 6 232, 7	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0 0 DD 0 DD 0 DD 0 0 0 0 0 0 0 0 0 0 0	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 155 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 264.3	6 B2: UP erative IE S 6 7 9 % * * * * * * * * * * * * *	DRS-III UPDRS- 5D 1 8 10 9 .4 8 10 9 .4 4 20 17 15 15 8	13 70 11 during (11 11 17 : 6 25 : 13 72 1 13 72 1 13 5.7% 31.9% 2.7% 2.5.4% 2.7% 13.6%	14.7% : 15.7% : 00.0% 2 Dn-period : Mean : 16.4% : 21.3% : 3.4% : 00.0% : 16.4% : 21.3% : 3.4% : 20.7% : 00.0% : 198.700 : 233.80 : 483.00 : 506.71 : 502.20 :	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 3.92 [16.27, 31.51 4 Mean Difference IV. Random, 95% 15.60 [11.77, 40.2 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 10.16]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.1 preoper <u>Mean</u> 33.5 23.5 23.8 Chi ² = 10 01 (P < 0. preope Mean 674.2 612.7 1,044	21.3 2.79, df = 5 00001) 12.8 10.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) erative LEI 267.8 230.4 287.5 798.6	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0 0 DD 0 DD 0 DD 0 0 0 0 0 0 0 0 0 0 0	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 155 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 264.3	6 B2: UP S 6 7 2 9 % * * * * * * * * * * * * *	DRS-III UPDRS- 50 4.4 8 10 9.9 .4 C: 1 0 DD Total 1 6 17 25 5 15	13	14.7% : 15.7% : 00.0% 2 Dn-period : Mean : 16.4% : 21.3% : 3.4% : 00.0% : 16.4% : 21.3% : 3.4% : 20.7% : 00.0% : 198.700 : 233.80 : 483.00 : 506.71 : 502.20 :	4.00 [-9.03, 17.0 3.92 [16.27, 31.5] d Mean Difference <u>IV. Random. 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.34, 10.5 9.52 [4.86, 14.1 10.16] 9.52 [4.86, 14.1 10.16]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.) preoper Mean 33.5 23.5 411 22.5 23.8 Chi ² = 10 11 (P < 0.) preoper Mean 674.2 612.7 1,044 965.7 616.5	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0.91, df = 4 0001) 0.91, df = 4 0001) 0.92, df = 2 202, 4 287, 5 798, 6 232, 7	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0 CD Total 6 17 25 15 8 14	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 155 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 264.3	6 B2: UP erative LE S 6 7 9 % * S 4 17.7 02.5 37.6 40.7	1 DRS-III UPDRS. 5D 32 4 4 8 10 .9 .4 4 5 5 5 5 15 15 8 14	13 70 11 during (d 11 International field 6 25 13 13 72 13 72 LEDD Weight Value 2,7% 2,7% 2,7% 13,6% 2,0,8%	14.7% : 15.7% 2 15.7% 2 15.7% 2 20.0% 2 20.7% 2 00.0% 2 198.70 233.80 00.0% 483.00 506.77 352.20 356.00	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.34, 10.5 9.52 [4.86, 14.1 h Difference <u>IV. Fixed, 95% CI</u> [-91.24, 488, 64] [10.81, 356.79] [345.15, 620.85] [08.05, 928.35] [163.77, 540.63] [203.76, 508.24]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.) preoper Mean 33.5 23.5 411 22.5 23.8 Chi ² = 10 11 (P < 0.) preoper Mean 674.2 612.7 1,044 965.7 616.5 658.9	21.3 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 0001) 0001) 0001 0001 267.8 230.4 287.5 798.6 232.7 257.8	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0 72 (P = 0.0 72 72 (P = 0.0 72 17 17 25 15 8 14 85	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 155 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 264.3	6 B2: UP erative LE S 6 7 9 % * S 4 17.7 02.5 37.6 40.7	1 DRS-III UPDRS. 5D 32 4 4 8 10 .9 .4 4 5 5 5 5 15 15 8 14	13 70 11 during (d 11 International field 6 25 13 13 72 13 72 LEDD Weight Value 2,7% 2,7% 2,7% 13,6% 2,0,8%	14.7% : 15.7% 2 15.7% 2 15.7% 2 20.0% 2 20.7% 2 00.0% 2 198.70 233.80 00.0% 483.00 506.77 352.20 356.00	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 3.92 [16.27, 31.51 4 Mean Difference IV. Random, 95% 15.60 [11.77, 40.2 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [5.27, 9.3 4.30 [-2.34, 10.9 9.52 [4.86, 14.1 10.16]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference 0 25 ve effective	51
45.5 Chi ² = 12 3 (P < 0.) preoper Mean 33.5 23.5 411 22.5 23.8 Chi ² = 10 11 (P < 0.) preoper Mean 674.2 612.7 1,044 965.7 616.5 658.9	21.3 2.79, df = 5 00001) 2.79, df = 5 00001) 12.8 10.8 14.7 4.3 7.8 0.91, df = 4 0001) 267.8 230.4 287.5 798.6 232.7 257.8 = 0.13); l ² :	13 70 (P = 0.0 RS-III 11 17 6 25 13 72 (P = 0.0 72 (P = 0.0 72 72 6 17 25 15 8 14 85	41.5 3); I ² = 619 <u>Mean</u> 17.9 16.5 155 15.2 19.5 3); I ² = 639 <u>Mean</u> 475.5 2 378.9 1 561 2 459 2 264.3	6 B2: UP erative LE S 6 7 9 % * S 4 17.7 02.5 37.6 40.7	1 DRS-III UPDRS. 5D 32 4 4 8 10 .9 .4 4 5 5 5 5 15 15 8 14	13 70 11 during (d 11 International field 6 25 13 13 72 13 72 LEDD Weight Value 2,7% 2,7% 2,7% 13,6% 2,0,8%	14.7% : 15.7% 2 15.7% 2 15.7% 2 20.0% 2 20.7% 2 00.0% 2 198.70 233.80 00.0% 483.00 506.77 352.20 356.00	4.00 [-9.03, 17.0 3.92 [16.27, 31.51 d Mean Difference <u>IV. Random, 95%</u> 15.60 [7.14, 24.0 7.00 [0.61, 13.3 26.00 [11.77, 40.2 7.30 [-2.34, 10.5 9.52 [4.86, 14.1 h Difference <u>IV. Fixed, 95% CI</u> [-91.24, 488, 64] [10.81, 356.79] [345.15, 620.85] [08.05, 928.35] [163.77, 540.63] [203.76, 508.24]	3] 3] -100 €] 6] 9] 3] 3] 4]	Mean Mean IV. Rau -50 -25 noneffecti	ve effective Difference a a b c c c c c c c c c c c c c	51
	73 42 51.4 (P = 59.1 (P = 0.00) Mear 42.0 33.6.7 53.2 53.2 55.0 53.2 55.0 53.2 55.0 53.2 55.0 53.2 55.0 55.0 55.0 55.0 55.0 55.0 55.0 55	73 18.6 42 10 51.4 10.9 51.4 10.9 Chi ² = 59.51, df = 4 (F (P = 0.0003) preoperative ai Mean SD 42.5 6.8 35.2 12.5 53.2 10.5 14.6 6.1 55.5 16.5 ; Chi ² = 13.13, df = 64 (P = 0.0003) preoperative UPDD Mean 46.2 19.6 42.4 10.7 48.3 16.6	73 18.6 42 10 51.4 10.9 51.4 10.9 Chi? = 59.51, df = 4 (P < 0.000)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	73 18.6 6 17 10.3 6 17.9% 56.00 [38.99, 73.01] 42 10 15 8.5 7.1 15 22.0% 33.50 [27.29, 39.71] 51.4 10.9 10 28.4 10.3 10 21.1% 23.00 [13.71, 32.29] T5 75 100.0% 28.68 [13.17, 44.20] ChP = 59.51, df = 4 (P < 0.00001); P = 93% (P = 0.0003) A2: bending angle during On-period Mean Difference Mean I Mean SD Total Mean SD Total Weight IV. Random, 95% Cl IV. Random, 95% Cl V. Random, 95% Cl IV. Random, 95% Cl 42.5 6.8 7 29 12.8 7 14.7% 13.50 [2.76, 24.24] 10 10 25 20.8 18.9, 9.38] 10 10 10.62, 26.02] 10 10.80 10.89, 11.83, 25.97] 14.6 6.1 15 7.1 6.5 15 25.5% 7.50 [2.99, 12.01] 55.5 16.5 14 38.7 21.1 14 10.89 [2.91, 7, 30.83] 10.5 10.65 10.69 [4.	73 18.6 6 17 10.3 6 17.9% 56.00 [38.99, 73.01] 42 10 15 8.5 7.1 15 22.0% 33.50 [27.29, 39.71] 51.4 10.9 10 28.4 10.3 10 21.1% 23.00 [13.71, 32.29] 75 75 100.0% 28.68 [13.17, 44.20] ChP = 59.51, df = 4 (P < 0.00001); P = 93% (P = 0.0003) A2: bending angle during On-period Mean Difference Mean Difference Mean SD Total Mean SD Total Weight IV. Random, 95% Cl IV. Random, 95% Cl 42.5 6.8 7 29 12.8 7 14.7% 13.50 [2.76, 24.24]

Fig. 3. Comparisons of clinical data between pre- and post-STN-DBS. A1: comparison bending angle between pre- and post-STN-DBS during Off-period; A2: comparison bending angle between pre- and post-STN-DBS during On-period; B1: comparison UPDRS-III between pre- and post-STN-DBS during Off-period; B2: comparison UPDRS-III between pre- and post-STN-DBS during On-period; C: comparison LEDD between pre- and post-STN-DBS. DBS, deep brain stimulation; STN, subthalamic nucleus; UPDRS-III, the Unified Parkinson's Disease Rating Scale III; LEDD, L-dopa equivalent daily dose.

Table 1. Clinical characteristics of the studies and participants included in this meta-analysis.

Authors	Years	Study Type	Method	Participants	Mean age (Years)	Gender (M/F)	Duration of PD (Years)	Duration of Camptocormia (Months)	Evidence Level	Follow-up (Months)
Lai et al. [3]	2021	Retrosp obs cohort	STN	10	Ν	Ν	Ν	N	III	6.0 ± 2.2
Lai <i>et al.</i> [8]	2021	Retrosp obs cohort	GPi	11	Ν	Ν	Ν	Ν	III	7.3 ± 3.3
Liang et al. [9]	2020	Prosp trail	STN	15	62.5 ± 8.1	7/8	10.5 ± 4.5	25.2 ± 10.8	II	6
Schlenstedt et al. [26]	2019	Retrosp obs cohort	STN	27	Ν	Ν	Ν	Ν	III	6–12
Sakai <i>et al.</i> [10]	2017	Retrosp obs cohort	STN	14	51.9 ± 9.7	8/6	13.1 ± 4.9	40.8 ± 22.8	III	6
Yamada et al. [11]	2016	Prosp trail	STN	17	66.4 ± 6.8	7/10	12.9 ± 6.0	48.2 ± 34.6	II	≥ 3
Schulz-Schaeffer et al. [12]	2015	Retrosp obs cohort	STN	25	67.1 ± 4.8	21/4	15.4 ± 4.0	$62.4 \pm N$	III	6-12
Umemura et al. [13]	2010	Case series	STN	8	65.1 ± 6.3	2/6	15.5 ± 4.8	Ν	IV	12
Sako <i>et al</i> . [14]	2009	Case series	STN	6	51.2 ± 5.9	2/4	9.0 ± 2.3	Ν	IV	Ν
Soares et al. [15]	2019	Case series	STN	2	65.5 ± 6.4	1/1	10.5 ± 2.1	5.3 ± 5.3	IV	8-12
Roediger et al. [16]	2019	Retrosp obs cohort	STN	3	Ν	Ν	Ν	Ν	III	15.4 ± 11.0
Pandey et al. [17]	2016	Case report	STN	1	58	1/0	7	60	IV	3
Ekmekci et al. [18]	2016	Case report	STN	1	51	0/1	10	Ν	IV	6
Lyons et al. [19]	2012	Case report	STN	1	63	0/1	19	228	IV	3
Asahi et al. [20]	2011	Case series	STN	4	62.8 ± 4.2	2/2	11.5 ± 1.7	62.4 ± 27.8	IV	25.8 ± 9.8
Capelle et al. [21]	2011	Case series	STN	2	69.0 ± 5.7	2/0	13.5 ± 2.1	Ν	IV	21
Yamada et al. [22]	2006	Case report	STN	1	71	0/1	11	Ν	IV	3
Hellmann et al. [23]	2006	Case report	STN	1	53	Ν	25	228	IV	10
Capelle et al. [21]	2011	Case report	GPi	1	64	1/0	10	Ν	IV	21
Thani et al. [24]	2011	Case report	GPi	1	57	0/1	13	24	IV	14
Micheli et al. [25]	2005	Case report	GPi	1	62	1/0	9	2	IV	3

Obs, observational; Prosp, prospective; Retrosp, retrospective; PD, Parkinson's disease; STN, subthalamic nucleus; GPi, globus pallidus internus; F, female; M, male; N, not available.

					· ·	-	•				
Authors	Method	Bending angle (Off)		Bending angle (On)		UPDRS-III (Off)		UPDRS-III (On)		LEDD	
unors memou		Pre-DBS	Post-DBS	Pre-DBS	Post-DBS	Pre-DBS	Post-DBS	Pre-DBS	Post-DBS	Pre-DBS	Post-DBS
Yamada et al. [11]	STN	84.0 ± 29.5	54.8 ± 28.3	59.6 ± 25.5	51.9 ± 28.9	42.4 ± 10.7	18.8 ± 8.8	23.5 ± 10.8	16.5 ± 8.0	612.7 ± 230.4	378.9 ± 117.7
Sakai <i>et al.</i> [10]	STN	Ν	Ν	55.5 ± 16.5	38.7 ± 21.1	45.5 ± 21.3	41.5 ± 11.0	23.8 ± 7.8	19.5 ± 9.4	658.9 ± 257.8	302.9 ± 134.2
Schlenstedt et al. [26]	STN	42.2 ± 7.5	35.5 ± 12.0	35.2 ± 12.5	32.9 ± 14	Ν	Ν	Ν	Ν	Ν	Ν
Liang et al. [9]	STN	42.0 ± 10.0	8.5 ± 7.1	14.6 ± 6.1	7.1 ± 6.5	55.1 ± 17.4	24.3 ± 12.2	Ν	Ν	965.7 ± 798.6	459.0 ± 237.6
Lai <i>et al.</i> [3]	STN	51.4 ± 10.9	28.4 ± 10.3	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν
Lai <i>et al</i> . [8]	GPi	42.9 ± 9.9	28.5 ± 10.7	Ν	Ν	Ν	Ν	62.9 ± 19.5	Ν	Ν	Ν
Schulz-Schaeffer et al. [12]	STN	Ν	Ν	53.2 ± 10.0	34.3 ± 15.0	Ν	Ν	22.5 ± 4.3	15.2 ± 2.9	1044.0 ± 287.5	561.0 ± 202.5
Umemura et al. [13]	STN	Ν	Ν	Ν	Ν	50.6 ± 17.2	20.4 ± 10.4	28.6 ± 11.6	Ν	616.5 ± 232.7	264.3 ± 140.7
Sako et al. [14]	STN	73 ± 18.6	17.0 ± 10.3	Ν	Ν	48.3 ± 16.6	15.0 ± 10.0	41.0 ± 14.7	15.0 ± 10.0	Ν	Ν
Case reports. [15-23]	STN	Ν	Ν	42.5 ± 6.8	29.0 ± 12.8	46.2 ± 19.6	23.8 ± 13.9	33.5 ± 12.8	17.9 ± 6.4	674.2 ± 267.8	475.5 ± 244.1
Case reports. [21,24,25]	GPi	Ν	Ν	Ν	Ν	41.3 ± 14.4	25.0 ± 11.5	Ν	Ν	708.3 ± 518.6	675.0 ± 330.7

Table 2. Clinical data of participants assessed pre- and post-DBS.

DBS, deep brain stimulation; STN, subthalamic nucleus; GPi, globus pallidus internus; LEDD, L-dopa equivalent daily dose; UPDRS-III, the Unified Parkinson's Disease Rating Scale

III; N, not available.

Table 3. Correlation analysis between clinical data and decreased angle of camptocormia after DBS.

	Decreased angle after D	BS in On-period	Decreased angle after DBS in Off-period			
	Pearson Correlation	<i>p</i> -value	Pearson Correlation	<i>p</i> -value		
Age	-0.241	0.107	-0.275	0.095		
Duration of PD	0.128	0.398	-0.269	0.102		
Duration of CC	-0.104	0.493	-0.433*	0.013*		
LEDD	-0.062	0.748	-0.404	0.136		
Pre-bending angle (On)	0.157	0.298	-0.241	0.184		
Pre-bending angle (Off)	0.036	0.845	0.352*	0.030*		
Pre-UPDRS-III (On)	-0.023	0.939	-0.070	0.895		
Pre-UPDRS-III (Off)	0.036	0.852	0.081	0.728		

DBS, deep brain stimulation; PD, Parkinson's disease; CC, Camptocormia; LEDD, L-dopa equivalent daily dose.

period (31.5 \pm 21.4 vs. 53.6 \pm 22.7, respectively; p < 0.0001, Fig. 2). A similar improvement in the mean bending angle was observed between STN-DBS and GPi-DBS (23.3 \pm 33.1 vs. 14.4 \pm 14.6, respectively; t = 0.91, p = 0.36).

Subgroup analysis was performed to explore the effectiveness of STN and GPi-DBS. For the STN-DBS trials, the mean post-operative bending angles during both the Off- and On-periods were significantly reduced compared to the pre-operative period (32.1 \pm 22.7 vs. 55.4 \pm 24.1, p = 0.0003; and 33.1 \pm 21.5 vs. 43.7 \pm 20.6, p= 0.0003, respectively; Fig. 3A1,A2). The average postoperative UPDRS-III scores evaluated during the Off- and On-periods (24.9 \pm 13.6 vs. 47.2 \pm 17.3, p < 0.00001; and 16.7 ± 6.9 vs. 26.2 ± 10.7 , p < 0.0001, respectively, Fig. 3B1,B2), as well as the mean LEDD (430.1 \pm 207.3 mg/day vs. 814.2 ± 443.0 mg/day, p < 0.00001, respectively, Fig. 3C), were also significantly lower than during the pre-operative period. For GPi-DBS, the average bending angle post-DBS during the Off-period showed more improvement than pre-DBS (28.5 \pm 10.7 vs. 42.9 \pm 9.9, respectively, p < 0.001). However, there was few GPi-DBS study reported the changes of clinical variables during the On-period after surgery.

The correlation analysis between clinical data and decreased angle of camptocormia after DBS were listed in Table 3. Pearson correlation analysis showed that the decease in bending angle after DBS was negatively correlated with the duration of camptocormia (R = -0.433, p = 0.013, Table 3), whereas positively associated with the pre-bending angle (R = 0.352, p = 0.03, Table 3).

5. Discussion

Camptocormia is a common postural disorder that generally occurs during the advanced stage of PD. DBS is an effective treatment that can alleviate many motor and non-motor symptoms of PD patients in clinical practice. This meta-analysis found that the average post-operative UPDRS-III scores and mean LEDD were lower than during the pre-operative period, thus supporting the efficacy of DBS for the treatment of motor symptoms. The mean post-operative bending angles following both STN-DBS and GPi-DBS were also found to be significantly lower than in the pre-operative period, indicating that DBS can markedly improve camptocormia in PD patients. The underlying pathogenesis of camptocormia is still unclear, although the central pathophysiological mechanism is thought to play an important role in the occurrence and progression of this condition [28,29]. DBS may send high-frequency stimulation to reduce the firing frequency on GPi/STN, thereby inducing disinhibition of motor thalamic nuclei and ultimately exciting the motor cortex [30]. Therefore, we speculate the improvement of camptocormia following DBS occurs mainly through above mentioned central pathophysiological mechanism that alleviates dysregulation of the basal ganglia and dystonia [29].

We found that the decreased bending angle after DBS was negatively correlated with the duration of camptocormia, whereas positively associated with the pre-bending angle. This concurs with previous studies that found camptocormia duration of ≤ 1.5 or 2 years was associated with a greater decrease in the bending angle after DBS, whereas camptocormia of >40 months was unlikely to show improvement [12,27]. Together, these results support the theory that patients with longer duration of camptocormia experience less benefit from DBS. Peripheral mechanisms such as hyperactivity, fatty infiltration and edema of the paraspinal muscles may play more important roles in the later stage of camptocormia in PD [28]. However, DBS alleviates camptocormia mainly through central mechanisms. This may explain why patients with longer duration of camptocormia benefit less from DBS.

In this meta-analysis, STN-DBS was observed to show a similar decrease in the mean bending angle as GPi-DBS. Previous studies have also reported similar improvement of motor symptoms in PD patients [31,32]. However, GPi and STN each have advantages and disadvantages. For example, STN-DBS may be associated with a greater reduction of dopaminergic medication and alleviation of nonmotor symptoms than GPi-DBS, but also with a higher risk of cognitive deterioration over time. On the other hand, patients with more severe dyskinesia or gait disorders may benefit more from GPi-DBS [31,32]. Some authors have also suggested superiority of GPi-DBS for PD [33]. Therefore, the choice of whether to use GPi or STN for PD patients with camptocormia may depend on other motor and non-motor symptoms, such as tremor, dyskinesia, gait, cognition and mood.

This meta-analysis has several limitations. Firstly, the sample size was relatively small. Secondly, only English language studies were included, which might give rise to some bias. Thirdly, the included studies may have heterogeneity in camptocormia, PD characteristics and follow-up time.

6. Conclusions

DBS can improve camptocormia in PD patients. Patients in the early stage of camptocormia and with a greater bending angle may benefit more from DBS.

Abbreviations

PD, Parkinson's disease; DBS, deep brain stimulation; LEDD, L-dopa equivalent daily dose; STN-DBS, subthalamic nucleus deep brain stimulation; GPi-DBS, globus pallidus internus deep brain stimulation; TCC, total camptocormia; UCC, upper camptocormia.

Author Contributions

FW and XG participated in design, literature selection, data extraction, statistical analysis, and drafting the manuscript. LH and HZ performed study selection and statistical analysis. All authors also participated in analyzing results, revising the manuscript, and approving the final version of this manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

We would like to thank all participants in this study.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest.

References

- Srivanitchapoom P, Hallett M. Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities. Journal of Neurology, Neurosurgery and Psychiatry. 2016; 87: 75–85.
- [2] Ali F, Matsumoto JY, Hassan A. Camptocormia: Etiology, diagnosis, and treatment response. Neurology Clinical Practice. 2018; 8: 240–248.
- [3] Lai Y, Song Y, Huang P, Wang T, Wang L, Pan Y, *et al.* Subthalamic Stimulation for Camptocormia in Parkinson's Dis-

ease: Association of Volume of Tissue Activated and Structural Connectivity with Clinical Effectiveness. Journal of Parkinson's Disease. 2021; 11: 199–210.

- [4] Fasano A, Geroin C, Berardelli A, Bloem BR, Espay AJ, Hallett M, *et al.* Diagnostic criteria for camptocormia in Parkinson's disease: a consensus-based proposal. Parkinsonism and Related Disorders. 2018; 53: 53–57.
- [5] Ruttiman R, Eltorai AEM, Daniels AH. Etiology and Management of Spinal Deformity in Patients With Parkinson's Disease. International Journal of Spine Surgery. 2018; 12: 15–21.
- [6] Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson's disease. Journal of Neural Transmission. 2016; 123: 19–30.
- [7] Ameghino L, Bruno V, Merello M. Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: an Exploratory Case-Control Study. Clinical Neuropharmacology. 2018; 41: 123–128.
- [8] Lai Y, Song Y, Su D, Wang L, Zhang C, Sun B, et al. Pallidal stimulation as treatment for camptocormia in Parkinson's disease. NPJ Parkinson's Disease. 2021; 7: 8.
- [9] Liang S, Yu Y, Li H, Wang Y, Cheng Y, Yang H. The Study of Subthalamic Deep Brain Stimulation for Parkinson Disease-Associated Camptocormia. Medical Science Monitor. 2020; 26: e919682.
- [10] Sakai W, Nakane S, Urasaki E, Toyoda K, Sadakata E, Nagaishi A, et al. The Cross-Sectional Area of Paraspinal Muscles Predicts the Efficacy of Deep Drain Stimulation for Camptocormia. Journal of Parkinson's Disease. 2017; 7: 247–253.
- [11] Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Subthalamic nucleus stimulation improves Parkinson's disease-associated camptocormia in parallel to its preoperative levodopa responsiveness. Journal of Neurology, Neurosurgery and Psychiatry. 2016; 87: 703–709.
- [12] Schulz-Schaeffer WJ, Margraf NG, Munser S, Wrede A, Buhmann C, Deuschl G, *et al.* Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration. Movement Disorders. 2015; 30: 368–372.
- [13] Umemura A, Oka Y, Ohkita K, Yamawaki T, Yamada K. Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease. Journal of Neurosurgery. 2010; 112: 1283– 1288.
- [14] Sako W, Nishio M, Maruo T, Shimazu H, Matsuzaki K, Tamura T, et al. Subthalamic nucleus deep brain stimulation for camptocormia associated with Parkinson's disease. Movement Disorders. 2009; 24: 1076–1079.
- [15] Soares C, Vilas-Boas MDC, Lopes EM, Choupina H, Soaresdos-Reis R, Fitas D, *et al.* Automated and objective measures of gait dynamics in camptocormia Parkinson's Disease subthalamic deep brain stimulation. Clinical Neurology and Neurosurgery. 2019; 186: 105537.
- [16] Roediger J, Artusi CA, Romagnolo A, Boyne P, Zibetti M, Lopiano L, *et al.* Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: a blind computerized analysis. Parkinsonism and Related Disorders. 2019; 62: 122–127.
- [17] Pandey S, Garg H. Postural & striatal deformities in Parkinson' s disease: Are these rare? Indian Journal of Medical Research. 2016; 143: 11–17.
- [18] Kaptan H, Ekmekci H. Camptocormia and deep brain stimulation: the interesting overlapping etiologies and the therapeutic role of subthalamic nucleus-deep brain stimulation in Parkinson disease with camptocormia. Surgical Neurology International. 2016; 7: 103.
- [19] Lyons M, Boucher O, Patel N, Birch B, Evidente V. Long-term benefit of bilateral subthalamic deep brain stimulation on camptocormia in parkinson's disease. Turkish Neurosurgery. 2012; 22: 489–92.

- [20] Asahi T, Taguchi Y, Hayashi N, Hamada H, Dougu N, Takashima S, *et al.* Bilateral Subthalamic Deep Brain Stimulation for Camptocormia Associated with Parkinson's Disease. Stereotactic and Functional Neurosurgery. 2011; 89: 173–177.
- [21] Capelle H, Schrader C, Blahak C, Fogel W, Kinfe TM, Baezner H, et al. Deep brain stimulation for camptocormia in dystonia and Parkinson's disease. Journal of Neurology. 2011; 258: 96–103.
- [22] Yamada K, Goto S, Matsuzaki K, Tamura T, Murase N, Shimazu H, *et al.* Alleviation of camptocormia by bilateral subthalamic nucleus stimulation in a patient with Parkinson's disease. Parkinsonism and Related Disorders. 2006; 12: 372–375.
- [23] Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Movement Disorders. 2006; 21: 2008–2010.
- [24] Thani NB, Bala A, Kimber TE, Lind CRP. High-Frequency Pallidal Stimulation for Camptocormia in Parkinson Disease: Case Report. Neurosurgery. 2011; 68: E1501–E1505.
- [25] Micheli F, Cersósimo MG, Piedimonte F. Camptocormia in a patient with Parkinson disease: beneficial effects of pallidal deep brain stimulation. Journal of Neurosurgery. 2005; 103: 1081– 1083.
- [26] Schlenstedt C, Gavriliuc O, Boße K, Wolke R, Granert O, Deuschl G, et al. The Effect of Medication and Deep Brain Stimulation on Posture in Parkinson's Disease. Frontiers in Neurol-

ogy. 2019; 10: 1254.

- [27] Chan AK, Chan AY, Lau D, Durcanova B, Miller CA, Larson PS, *et al.* Surgical management of camptocormia in Parkinson's disease: systematic review and meta-analysis. Journal of Neurosurgery. 2019; 131: 368–375.
- [28] Magrinelli F, Geroin C, Squintani G, Gandolfi M, Rizzo G, Barillari M, et al. Upper camptocormia in Parkinson's disease: Neurophysiological and imaging findings of both central and peripheral pathophysiological mechanisms. Parkinsonism and Related Disorders. 2020; 71: 28–34.
- [29] Lepoutre A, Devos D, Blanchard-Dauphin A, Pardessus V, Maurage C, Ferriby D, *et al.* A specific clinical pattern of camptocormia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2006; 77: 1229–1234.
- [30] Tierney TS. Deep brain stimulation foundations and future trends. Frontiers in Bioscience. 2018; 23: 162–182.
- [31] Ramirez-Zamora A, Ostrem JL. Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease. JAMA Neurology. 2018; 75: 367.
- [32] Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease. New England Journal of Medicine. 2010; 362: 2077–2091.
- [33] Tagliati M. Turning tables: should GPi become the preferred DBS target for Parkinson disease? Neurology. 2012; 79: 19– 20.